| ￥3500 | |
| Z05684-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Purity | > 95% as determined by BisTris PAGE | ||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 17.9 kDa (CD94) and 18.3 kDa (NKG2A) | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 33-48 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Serial dilutions of Anti-NKG2A Antibody were added into NKG2A&CD94, His & Avi, Flag Human, His Tag : Biotinylated Human HLA-E Complex Tetramer, His Tag binding reactioins. The half maximal inhibitiory concentration(IC50) is 31.8ng/ml. »
Immobilized NKG2A&CD94, His & Avi, Flag Human, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Anti-NKG2A Antibody, hFc Tag with the EC50 of 2.9ng/ml determined by ELISA. »
The purity of NKG2A&CD94, His & Avi, Flag Human is greater than 95% as determined by SEC-HPLC. »
NKG2A&CD94, His & Avi, Flag Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | The ligand-receptor assignment between HLA-G and NKG2A/CD94 is dependent of the amino acid composition in the HLA-G heavy chain. Understanding the biophysical basis of receptor-mediated events that lead to NK cell inhibition would help to remove non-tumor reactive cells and support personalized mild autologous NK cell therapies. |
| Synonyms | CD159a; NKG2A; NKG2-A; CD94; NKG2A&CD94 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
